pretickt

Is VRTX a good stock to buy?

Vertex Pharmaceuticals Incorporated · end-of-day data as of Nov 13, 2026

Vertex
VRTX · $137B
$538.60-0.7%
Nov 13, 2026 · close
$500$550SepOctNov9:3016:003 months +2.0%Nov 13 · close
▲ 6
  • PT$574.33 +6.6%
  • ConsensusBuy · 33
  • Trendbullish
  • MAs4 of 4
  • MA20×50Golden 5d ago
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • P/E34.7x
  • RSI53
  • Support-1.2%
  • Resistance+3.3%
  • Off 52w high-5.3%
  • Volume0.5x
  • Bollingerupper half
  • News1.00
  • FCF yield+2.3%
  • P/E vs sector+7.6%
  • 52w range$412–$569
  • ATR+2.9%
  • Off ATH-5.3%
▼ 3
  • P/E vs own+16.9%
  • Insiders-$6.31M
  • MACD-0.14

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Vertex a good stock to buy?

Vertex is strong on 2 of the 5 questions about the business; weak on execution and fragility. The price is high: 34.7 times its earnings, above its 3-year median of 27.4 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage some edge
  3. Economics profits growing
  4. Execution misses
  5. Fragility fragile
  6. Price expensive
DemandDo people want more of what it sells?growing

VRTX sales growth revenue growth

+10%a year, for the last 3 years

Vertex's sales grew 10% a year for 3 years, to $12.04B in fiscal 2025.

VRTX analysts' forecast revenue estimates

+10%the sales they expect next fiscal year, on the last

Analysts expect Vertex's sales to grow 10% to $13.26B in fiscal 2026 (21 analysts).

VRTX competitors

pretickt analysis+11%its sales in 12 months, on a year before

Vertex's sales grew 11% in the 12 months to Sep 30, 2026, slower than Alnylam (+56%), Incyte (+25%), Regeneron (+19%) and Moderna (+14%).

VRTX sales by business revenue by segment

86%of its sales from TRIKAFTA/KAFTRIO

TRIKAFTA/KAFTRIO brought Vertex 86% of its sales in fiscal 2025; ALYFTREK 7%.

Advantage moatIs it hard to copy?some edge

VRTX margin on each sale gross margin

86%left after making the product

Vertex kept 86% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 82%.

EconomicsDoes it make good money?profits growing

VRTX cash generated free cash flow

$3.2Bcash left after investing, last 12 months

Vertex generated $3.2B of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.

ExecutionDoes it deliver what it promises?misses

VRTX earnings vs estimates

3 of 7quarters above the analysts' estimate

Vertex beat the analysts' profit estimate in 3 of 7 quarters, the latest on Nov 2, 2026; 1 quarter the sources disagree on is left out.

VRTX insider selling

-$155Msold, net, by its executives in 12 months

Vertex's executives and directors sold a net $155M of shares in the 12 months to Nov 13, 2026; none bought.

VRTX number of employees

+5%more people in a year

Vertex had 6,400 employees at the end of fiscal 2025, 5% more than a year before.

VRTX CEO pay

$21.14Mfor fiscal 2025, 71% of it in stock and options

Vertex paid its CEO $21.14M for fiscal 2025, 71% of it in stock and options.

Fragility risksCould something break it?fragile

VRTX financial health Altman Z-score

8.8Altman Z-score, safe above 3

Vertex's Altman Z-score is 8.8 (Nov 13, 2026), above 3, where the safe zone starts.

VRTX quality checks Piotroski score

3 of 9checks passed

Vertex passes 3 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets, cash against profit, long-term debt, the current ratio, gross margin and sales for its assets.

VRTX biggest customers

34%of sales from its 2 biggest customers

McKesson Corporation and Accredo Health Group, Inc. made 34% of Vertex's sales in fiscal 2025.

VRTX in past recessions

pretickt analysis-42%its sales in the worst one

Vertex's sales fell in 1 of the last 2 US recessions, by as much as 42% in fiscal 2009.

Price valuationIs the price reasonable?expensive

VRTX price vs profit P/E ratio

34.7×a year's earnings

Vertex's P/E ratio is 34.7 (Nov 13, 2026), above its 3-year median of 27.4.

VRTX price vs competitors

pretickt analysis34.7×a year's earnings, against its competitors

Investors pay 34.7 times Vertex's earnings (Nov 13, 2026), more than for Regeneron (21.1) and Alnylam (8.3), less than for Incyte (64.3).

VRTX analysts' target price target

+7%to their average target

Analysts' average price target for Vertex is $574, 7% above the Nov 13, 2026 close of $538.60.

VRTX growth priced in fair value

pretickt analysis+17%a year, for ten years, to be worth the price

At $538.60 a share, Vertex's free cash flow must grow about 17% a year for ten years to be worth the price (Nov 13, 2026).

What is Vertex's P/E ratio?

Vertex's P/E ratio is 34.7 (Nov 13, 2026), above its 3-year median of 27.4. Investors pay 34.7 times Vertex's earnings (Nov 13, 2026), more than for Regeneron (21.1) and Alnylam (8.3), less than for Incyte (64.3).

Who are Vertex's biggest competitors?

pretickt compares Vertex with Regeneron, Moderna, Incyte and Alnylam. Vertex's sales grew 11% in the 12 months to Sep 30, 2026, slower than Alnylam (+56%), Incyte (+25%), Regeneron (+19%) and Moderna (+14%).

Are insiders selling Vertex stock?

Vertex's executives and directors sold a net $155M of shares in the 12 months to Nov 13, 2026; none bought.

How does Vertex make money?

TRIKAFTA/KAFTRIO brought Vertex 86% of its sales in fiscal 2025; ALYFTREK 7%.

How many employees does Vertex have?

Vertex had 6,400 employees at the end of fiscal 2025, 5% more than a year before.

Who are Vertex's biggest customers?

McKesson Corporation and Accredo Health Group, Inc. made 34% of Vertex's sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.